Liquidia Corporation (LQDA) is in Healthcare, Drug Manufacturers - Specialty & Generic, based in United States, listed on NasdaqCM. Market cap 2.51B USD. 52-week range 21.94 to 93.61 USD. Trailing P/E 20.2. Data as of 2026-10-09.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous ...